Merus and its pipeline of bispecific antibodies are attracting growing investor interest, with the first data from a Keytruda-based combination in head and neck cancer being eagerly anticipated in Q2.
The Utrecht, Netherlands and Cambridge, MA-based company has been around since 2003, but has seen its market cap double over...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)